Therefore, fusion proteins involving IL-3 and GM-CSF have been designed to prevent thrombocytopenia in chemotherapy-treated patients with certain cancer types (Curtis et al., 1991; Vadhan-Raj et al., 1994; O’Shaughnessy et al., 1996). Here, CSF2 is linked to cancer.